Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Gastrointestinal Reflux Diseases and Changing Lifestyle
4.2.2 Increasing Awareness about GERD
4.3 Market Restraints
4.3.1 Patent Expiry of Blockbuster Drugs
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Diagnosis
5.1.1.1 Upper Endoscopy
5.1.1.2 Ambulatory Acid (pH) Probe Test
5.1.1.3 Esophageal Manometry
5.1.1.4 Others
5.1.2 Drug Type
5.1.2.1 H-2-receptor Blockers
5.1.2.2 Proton Pump Inhibitors
5.1.2.3 Others
5.2 Geography
5.2.1 North America
5.2.1.1 US
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 UK
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 GlaxoSmithKline PLC
6.1.2 SRS Life Sciences
6.1.3 Johnson & Johnson Services, Inc.
6.1.4 Medtronic Plc
6.1.5 Olympus Corporation
6.1.6 Pfizer, Inc.
6.1.7 Reckitt Benckiser Group PLC
6.1.8 Takeda Pharmaceutical Co., Ltd.
6.1.9 Teva Pharmaceuticals Industries Limited.


7 MARKET OPPORTUNITIES AND FUTURE TRENDS